Sudafed

Sudafed is a consumer healthcare brand associated primarily with over-the-counter medicines for nasal and sinus congestion. The brand is best known in the United States for products containing pseudoephedrine, a systemic decongestant, although the exact formulations, product names, ownership arrangements, and regulatory status differ by country. Some markets also sell Sudafed-branded products containing phenylephrine or other ingredients, meaning that the brand name does not identify one universal formula. In the United States, Sudafed is part of the consumer health portfolio operated by Kenvue. Its US range has included immediate-release and extended-release pseudoephedrine tablets, combination products for congestion and cold symptoms, and phenylephrine-based products sold through the Sudafed PE line. Because pseudoephedrine can be used in the illicit manufacture of methamphetamine, US sales are subject to federal purchasing controls and additional state requirements. These rules generally require products containing pseudoephedrine to be kept behind the pharmacy counter, with quantity limits and identification or sales-record requirements. The restrictions affect availability and purchasing procedures but do not make the brand a prescription medicine. Sudafed developed into a prominent name in the congestion-relief category through broad retail distribution, recognizable packaging, and product segmentation by symptom, duration, age group, and active ingredient. Typical positioning emphasizes temporary relief of blocked nasal passages, sinus pressure, and related cold symptoms rather than treatment of the underlying infection. Combination products may also address headache, fever, cough, or other symptoms, subject to the labeling and regulatory rules of the relevant market. The brand’s corporate history is linked to the evolution of large consumer-health businesses. Sudafed was formerly associated with Pfizer’s consumer healthcare operations and later became part of Johnson & Johnson’s consumer portfolio following Johnson & Johnson’s acquisition of Pfizer Consumer Healthcare. In 2023, Johnson & Johnson separated its consumer-health business into Kenvue, transferring the US Sudafed business into the newly independent consumer-health company. Brand ownership is not necessarily uniform worldwide, so a market-specific assessment is required when comparing Sudafed products internationally. Sudafed has also been affected by wider regulatory and scientific debates surrounding oral decongestants. In the United States, the Food and Drug Administration concluded in 2023 that available data did not support the effectiveness of orally administered phenylephrine at the standard recommended dose for nasal congestion and proposed removing that ingredient from the relevant over-the-counter monograph. The action concerns phenylephrine products, including products marketed under the Sudafed PE name, and does not apply in the same way to pseudoephedrine products. The episode illustrates the distinction between the Sudafed master brand and the active ingredients used in particular products. Today, Sudafed remains an active, widely recognized congestion-relief brand, but its portfolio is shaped by country-specific regulation, ingredient availability, pharmacy controls, and changes in consumer-health ownership. Its principal competitive setting includes other decongestant and cold-remedy brands, private-label pharmacy products, and non-drug measures for relieving congestion.

Sudafed is a branded line of nonprescription decongestant medicines. Its identity has traditionally been strongest in products containing pseudoephedrine, a sympathomimetic drug that reduces swelling in the nasal passages and can temporarily improve airflow during colds, allergies, and sinus congestion. The brand has also been used for products containing other active ingredients, particularly phenylephrine, and for combination medicines addressing several cold or sinus symptoms. The brand expanded through the development of multiple dosage forms and duration options. Immediate-release products were complemented by extended-release tablets marketed for longer-lasting relief, while combination products added ingredients intended to address symptoms such as headache, fever, cough, or runny nose. Product composition has varied by market and over time, so a Sudafed product must be identified by its local label and active-ingredient statement rather than by the brand name alone. Children's versions and age-specific formulations have likewise depended on local regulation and company portfolio decisions. In the United States, pseudoephedrine-containing Sudafed products became subject to increasingly restrictive retail controls because pseudoephedrine can be diverted for illicit methamphetamine production. The federal Combat Methamphetamine Epidemic Act of 2005, implemented in 2006, introduced requirements including behind-the-counter placement, purchaser identification, transaction records, and quantity limits. States have added or modified requirements in some cases. These rules created a clear distinction between pseudoephedrine Sudafed products and phenylephrine products that could generally remain on open retail shelves. Sudafed's corporate ownership followed the consolidation of the consumer-health industry. The brand was associated with Pfizer Consumer Healthcare before Pfizer sold that business to Johnson & Johnson in 2006. It subsequently sat within Johnson & Johnson's consumer-health operations alongside other over-the-counter medicine and personal-care brands. Johnson & Johnson later separated its consumer-health activities into Kenvue, which became an independent public company in 2023. The United States Sudafed business is operated by Kenvue, while rights and commercial arrangements in other countries can differ. A major recent issue for the brand involved the effectiveness of oral phenylephrine. In 2023, the US Food and Drug Administration announced that its review of available data did not support oral phenylephrine's effectiveness as a nasal decongestant at the standard recommended dose and proposed removing the ingredient from the relevant over-the-counter monograph. This regulatory process relates to phenylephrine products, including the Sudafed PE line, and should not be treated as a finding about pseudoephedrine products. The episode brought additional attention to active-ingredient distinctions within the Sudafed portfolio. Sudafed remains an active brand in the cold, allergy, and sinus-relief market. Its continuing role depends on country-specific medicine regulation, pharmacy restrictions, ingredient availability, consumer preference, and competition from other branded and private-label decongestants. The brand's broad recognition gives it value as a retail signifier for congestion relief, but its individual products must continue to meet changing standards for safety, efficacy, labeling, and responsible sale.

• 2023

  Kenvue separation from Johnson & Johnson

  [3]Kenvue completes separation from Johnson & Johnsonkenvue.com

  Kenvue became an independent public consumer-health company, with the US Sudafed business included in its portfolio.

• 2023

  FDA questions oral phenylephrine effectiveness

  [1]FDA proposes removing oral phenylephrine from the over-the-counter monographfda.gov

  The FDA proposed removing oral phenylephrine from the over-the-counter monograph after concluding that available data did not support effectiveness at the standard recommended dose.

• 2006

  US pseudoephedrine retail controls take effect

  [2]US Drug Enforcement Administration: Methamphetamine precursor chemical informationdeadiversion.usdoj.gov

  Federal requirements introduced behind-the-counter sales, identification, recordkeeping, and purchase limits for pseudoephedrine products, changing the retail experience for relevant Sudafed products.

• 2006

  Pfizer Consumer Healthcare is acquired by Johnson & Johnson

  [4]Johnson & Johnson completes acquisition of Pfizer Consumer Healthcarejnj.com

  Sudafed entered Johnson & Johnson's consumer-health portfolio through Johnson & Johnson's acquisition of Pfizer Consumer Healthcare.

Mainstream over-the-counter relief for temporary nasal and sinus congestion, with products differentiated by active ingredient, duration, symptom combination, and age group.

• Extended-release decongestant

  Sudafed 12 Hour

  An extended-release Sudafed format intended to provide longer-duration relief from nasal congestion than an immediate-release tablet. In the United States, the product name has been associated with pseudoephedrine formulations, which are subject to pharmacy-counter purchasing controls and federal quantity limits. Exact dosage and labeling should be checked against the local package.

• Extended-release decongestant

  Sudafed 24 Hour

  A once-daily or approximately 24-hour extended-release congestion-relief format sold in markets where the formulation is authorized. Product composition and availability differ by country; in the United States, the Sudafed name is associated with products whose active ingredients and purchasing conditions must be confirmed on the label.

• Phenylephrine-based decongestant

  Sudafed PE

  A Sudafed sub-line built around phenylephrine rather than pseudoephedrine in the United States. It was positioned as an accessible oral congestion-relief alternative that generally did not require behind-the-counter purchase. Its regulatory position became uncertain after the FDA proposed removing oral phenylephrine from the US over-the-counter monograph in 2023.

• Sinus and nasal congestion medicine

  Sudafed Sinus Congestion

  A product designation used for Sudafed medicines aimed at temporary relief of blocked nasal passages and sinus congestion. Depending on the market, products under this naming may use pseudoephedrine, phenylephrine, or a combination formulation. Consumers need to consult the local label for the active ingredient, dosage, age restrictions, and contraindications.

• 2023

  Transfer of the US brand business to KenvueStrategy

  Background

  Johnson & Johnson separated its consumer-health operations into a new independent company.

  Action taken

  Kenvue assumed the US Sudafed business as part of the transferred consumer-health portfolio.

  Aftermath

  Sudafed continued as an active Kenvue brand while remaining subject to market-specific ownership and licensing arrangements outside the United States.

  Source

• 2023

  Regulatory review of oral phenylephrineOther

  Background

  The FDA reviewed evidence concerning the effectiveness of oral phenylephrine, an ingredient used in the Sudafed PE segment.

  Action taken

  The FDA proposed removing oral phenylephrine from the over-the-counter monograph because available data did not support effectiveness at the standard recommended dose.

  Aftermath

  The proposal created uncertainty for phenylephrine-based congestion products, but it did not constitute the same finding for pseudoephedrine products.

  Source

• 2006

  Adaptation to federal pseudoephedrine controlsStrategy

  Background

  US controls introduced after the Combat Methamphetamine Epidemic Act made pseudoephedrine products subject to additional retail requirements.

  Action taken

  Relevant Sudafed products moved into controlled pharmacy-counter channels and became subject to purchaser verification, sales records, and quantity limits.

  Aftermath

  The policy separated the retail treatment of pseudoephedrine products from that of phenylephrine products and remains a defining feature of the US category.

  Source

1. 1FDA proposes removing oral phenylephrine from the over-the-counter monographfda.gov
2. 2US Drug Enforcement Administration: Methamphetamine precursor chemical informationdeadiversion.usdoj.gov
3. 3Kenvue completes separation from Johnson & Johnsonkenvue.com
4. 4Johnson & Johnson completes acquisition of Pfizer Consumer Healthcarejnj.com
5. 5Kenvue annual reports and filingsinvestors.kenvue.com